机构：[1]Key Laboratory of Chinese Materia Medica, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang 150040, China[2]Key Laboratory of Cardiovascular Medicine Research (Harbin Medical University), Ministry of Education, Harbin, Heilongjiang 150086, China[3]Department of Radiation Oncology, Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN 46022, USA[4]Department of Endocrinology, The Second affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150081, China[5]School of Traditional Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou, Guangdong 510006, China.
Lung cancer is a malignant tumor characterized by a rapid proliferation rate, less survivability, high mortality, and metastatic potential. This review focuses on updated research about the clinical application of traditional Chinese medicine (TCM) as an adjuvant therapy to lung cancer treatment and the mechanisms of TCM effect on lung cancer in vitro and in vivo. We summarized the recent 5 years of different research progress on clinical applications and antitumor mechanisms of TCM in the treatment of lung cancer. As a potent adjuvant therapy, TCM could enhance conventional treatments (chemotherapy, radiation therapy, and epidermal growth factor receptors [EGFRs] tyrosine kinase inhibitors [TKIs]) effects as well as provide synergistic effects, enhance chemotherapy drugs chemosensitivity, reverse drug resistance, reduce adverse reactions and toxicity, relieve patients' pain and improve quality of life (QOL). After treating with TCM, lung cancer cells will induce apoptosis and/or autophagy, suppress metastasis, impact immune reaction, and therapeutic effect of EGFR-TKIs. Therefore, TCM is a promisingly potent adjuvant therapy in the treatment of lung cancer and its multiple mechanisms are worthy of an in-depth study.
基金：
the National
Natural Science Foundation of China (No. 81773904),
the National Key R&D Program of China (No.
2018YFC1707101), and the National Major Scientific
and Technological Special Project for “Significant New
Drugs Development” (No. 2018ZX09731001), the Research
Fund Project of Heilongjiang University of
Traditional Chinese Medicine (No. 201720), the ResearchFund Project of Key Laboratory of Cardiovascular
Medicine Research (Harbin Medical University), Ministry
of Education (No. 2014012).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2019]版：
大类|3 区医学
小类|3 区医学：内科
最新[2025]版：
大类|2 区医学
小类|2 区医学：内科
第一作者：
第一作者机构：[1]Key Laboratory of Chinese Materia Medica, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang 150040, China[2]Key Laboratory of Cardiovascular Medicine Research (Harbin Medical University), Ministry of Education, Harbin, Heilongjiang 150086, China
共同第一作者：
通讯机构：[*1]School of Traditional Chinese Medicine, Guangdong Pharmaceutical University, No. 280 Huandong Road, Guangzhou, Guangdong 510006, China
推荐引用方式(GB/T 7714)：
Su Xiao-Lin,Wang Jiang-Wei,Che Hui,et al.Clinical application and mechanism of traditional Chinese medicine in treatment of lung cancer.[J].Chinese Medical Journal.2020,133(24):2987-2997.doi:10.1097/CM9.0000000000001141.
APA：
Su Xiao-Lin,Wang Jiang-Wei,Che Hui,Wang Chang-Fu,Jiang Hai...&Wang Qiu-Hong.(2020).Clinical application and mechanism of traditional Chinese medicine in treatment of lung cancer..Chinese Medical Journal,133,(24)
MLA：
Su Xiao-Lin,et al."Clinical application and mechanism of traditional Chinese medicine in treatment of lung cancer.".Chinese Medical Journal 133..24(2020):2987-2997
